The Hub-and-Spoke Framework: A Federated Organizational Model for Scaling Artificial Intelligence in the Pharmaceutical Industry

The Hub-and-Spoke Framework: A Federated Organizational Model for Scaling Artificial Intelligence in the Pharmaceutical Industry Prithvi Vasireddy College of Engineering Northeastern University Boston, MA Abstract—The pharmaceutical industry stands at the precipice of a transformation driven by Artificial Intelligence (AI), with projections estimating value creation of over $100 billion annually. However, realizing this potential is contingent upon establishing an organizational structure capable of scaling innovation responsibly and effectively. Traditional centralized or fully decentralized models for technology adoption have proven inadequate, leading to bottlenecks, siloed efforts, and inconsistent governance. This paper posits that a federated, hub-and-spoke organizational model provides the optimal framework for scaling AI across the pharmaceutical value chain. This model balances centralized strategic control and governance through an AI Center of Excellence (the hub) with decentralized, businessaligned innovation through embedded, cross-functional teams (the spokes). By analyzing AI’s impact on R&D, clinical development, manufacturing, and commercial operations, we detail the components, leadership roles, and operational dynamics of this hybrid structure. We further provide a technical blueprint for this model’s implementation, including reference cloud architectures on AWS and GCP, a federated data mesh strategy, and a GxP-compliant MLOps framework. This paper provides a comprehensive blueprint for pharmaceutical companies to build a sustainable foundation for AI-powered transformation. Index Terms—Artificial Intelligence, Organizational Structure, Pharmaceutical Industry, Hub-and-Spoke Model, Center of Excellence, Federated Governance, Digital Transformation, GxP Compliance, MLOps, Cloud Architecture, Data Mesh. I. INTRODUCTION The pharmaceutical industry is confronting an era of unprecedented technological disruption, with Artificial Intelligence (AI) emerging as a cornerstone of future innovation and value creation. The economic potential is staggering; the global AI in the pharmaceutical market is forecasted to expand from $1.8 billion in 2023 to $13.1 billion by 2034, reflecting a compound annual growth rate (CAGR) of 18.8% [1]. Projections from the McKinsey Global Institute suggest that AI could generate between $60 billion and $110 billion in annual economic value for the pharmaceutical and medicalproduct industries [2], [3], [4]. Further analysis indicates that strategic AI adoption could enable innovative pharmaceutical companies to more than double their operating margins, from 20% today to over 40% by 2030 [5]. This transformative potential stems from AI’s ability to accelerate drug discovery, optimize clinical trials, enhance manufacturing efficiency, and personalize commercial engagement. Despite this clear and compelling value proposition, a significant gap persists between AI’s potential and its scaled implementation. Many organizations find themselves mired in what can be described as a "scaling conundrum." They successfully execute pilot projects and proofs of concept but fail to transition these "islands of experimentation" into enterprise-wide, value-generating capabilities [6]. This is not a failure of technology but a fundamental misalignment between technology strategy and organizational design. One global pharmaceutical company, for instance, developed a successful machine learning tool to guide its sales force in a single country, but the initiative failed to propagate across the organization due to a highly decentralized structure that lacked the mechanisms for scaling proven innovations [6]. This scenario is common, with many companies struggling to identify and prioritize high-impact use cases, leaving high-value domains like manufacturing and supply chains significantly underutilized [5]. The result is a substantial value realization gap, where massive investments in AI fail to translate into the transformative, bottom-line impact that has been projected. This paper argues that the most critical challenge for pharmaceutical executives is not whether to invest in AI, but how to structure the organization to ensure that investment translates into scalable, enterprise-wide returns. The solution lies in adopting a federated, hub-and-spoke organizational model. This hybrid structure resolves the inherent tension between the need for centralized strategic control and the demand for decentralized, domain-specific agility. It provides a purpose-built framework that moves beyond the flawed paradigms of pure centralization or decentralization, offering a sustainable and effective blueprint for scaling AI across the complex, regulated pharmaceutical environment [7]. This model serves as the essential bridge across the value realization gap, enabling companies to harness AI’s full potential for sustained competitive advantage. II. THE AI IMPERATIVE ACROSS THE PHARMACEUTICAL VALUE CHAIN The transformative impact of AI is not confined to a single function but extends across the entire pharmaceutical lifecycle. From the earliest stages of research to post-market surveillance, AI offers opportunities to enhance speed, efficiency, and efficacy. Understanding the breadth of these applications is critical to appreciating the need for a versatile organizational structure that can support a diverse portfolio of use cases. A. Research & Development (R&D): Accelerating Discovery The traditional drug discovery process is notoriously long, expensive, and characterized by a high failure rate, with only about 10% of candidates successfully navigating clinical trials [1]. AI is fundamentally reshaping this paradigm by leveraging its capacity to analyze vast and complex biological and chemical datasets at a scale and speed unattainable through human effort alone. Key applications in R&D include target identification, molecule design, and precision medicine. AI algorithms can mine extensive databases of multi-omics data, scientific literature, and clinical trial results to identify and validate novel drug targets, thereby increasing the probability of clinical success [1], [8]. AstraZeneca, for example, has already incorporated its first AI-generated drug targets into its R&D portfolio, demonstrating the real-world viability of this approach [9]. In molecule design and screening, AI models can predict compound interactions, toxicity, and efficacy, analyzing hundreds of millions of molecules in seconds [10], [11]. This capability can dramatically shorten discovery timelines, with some estimates suggesting a reduction from 5-6 years to as little as one year [3]. The biotech firm Insilico Medicine leveraged AI to advance a drug candidate to Phase 1 clinical trials in 50% less time than traditional methods [5]. Furthermore, AI is a critical enabler of precision medicine, analyzing genomic and clinical data to identify patient subgroups and biomarkers that inform the development of highly targeted, personalized therapies [10]. B. Clinical Development: Optimizing Trials Clinical trials represent the most resource-intensive and time-consuming phase of drug development. AI is poised to address long-standing inefficiencies in trial design, patient recruitment, and data management. AI-powered platforms can optimize the selection of clinical trial sites by analyzing historical performance data, patient demographics, and protocol complexity to predict which sites will enroll patients most quickly and effectively. This approach has been shown to boost patient enrollment by 10-20% and compress overall development timelines by an average of six months per asset [12], [13]. Generative AI further streamlines operations by automating the drafting of trial documents such as study protocols, which can reduce associated process costs by up to 50% [12]. For trial management, AI-powered "copilots" can assist clinical trial managers by sifting through thousands of daily data points to prioritize critical issues and even suggest interventions, such as drafting targeted emails to underperforming sites [13]. Advanced techniques, such as the use of AI to create "digital twins" that predict a patient’s disease progression, can help reduce the required size of control arms in clinical trials, lowering costs and accelerating timelines [14]. The application of AI to patient recruitment for decentralized clinical trials (DCTs) can reduce the enrollment period by up to 30% [15]. C. Manufacturing and Supply Chain: Enhancing Efficiency and Quality AI applications in manufacturing and supply chain operations are projected to account for as much as 40% of the total value generated by AI in the pharmaceutical industry [5]. This domain is critical for achieving operational excellence, ensuring product quality, and maintaining supply chain resilience. A high-value use case is predictive maintenance, where AI algorithms analyze sensor data from manufacturing equipment to predict potential failures before they occur. This proactive approach minimizes costly unplanned downtime and is projected to generate approximately $10 billion in value by 2030 [1], [5]. Johnson & Johnson has successfully implemented predictive maintenance in its facility in India to reduce operational disruptions [5]. In quality control, AIpowered computer vision systems can inspect products on high-speed production lines in real-time, identifying defects with greater accuracy than conventional methods. This can boost quality control productivity by 50-100% and reduce process deviations by 65% [3], [5]. The Indian pharmaceutical company Cipla deployed an AI-based visual inspection system that reduced its false rejection rate from 2% to just 0.1%, significantly increasing throughput [5]. In the supply chain, AI enhances demand forecasting, optimizes inventory levels to prevent stockouts or waste, and helps mitigate disruption risks by analyzing a wide range of data, including market trends, weather patterns, and geopolitical events [1], [16]. D. Commercial Operations: Personalizing Engagement AI is also revolutionizing the commercial side of the pharmaceutical business, transforming how companies engage with healthcare professionals (HCPs), patients, and payers. This functional area is expected to capture 25-35% of AI’s total value potential [17]. Traditional commercial models are being replaced by hyperpersonalized engagement strategies driven by agentic AI. These systems can continuously analyze customer data to dynamically adjust call plans, scientific narratives, and sales pitches for each HCP in real-time, moving far beyond static "next best action" recommendations [18]. In marketing, AI algorithms analyze patient journey data, advertising metrics, and HCP interaction patterns to optimize omnichannel marketing campaigns and automate the generation of personalized content [8]. This data-driven approach not only improves the effectiveness of commercial efforts but also enhances operational efficiency by reducing administrative burdens and allowing sales representatives to focus on higher-value activities [18]. The systemic impact of AI across these diverse and highly specialized domains is summarized in Table I. The breadth and depth of these applications underscore the necessity for an organizational model that can support varied requirements, from long-term R&D projects to real-time operational optimizations. III. A CRITICAL REVIEW OF ORGANIZATIONAL PARADIGMS FOR AI SCALING The choice of an organizational model is not merely an operational decision; it is a primary determinant of success or failure in scaling complex technologies like AI. The model functions as a critical risk management strategy, as flawed structures can introduce significant enterprise risks, including compliance failures, security breaches, and wasted capital on non-scalable initiatives. An examination of traditional organizational paradigms reveals their inherent limitations in the context of AI adoption in the pharmaceutical industry. A. The Centralized Model: The Ivory Tower Bottleneck In a purely centralized model, a single corporate entity, such as an IT or a central data science department, maintains exclusive ownership over all aspects of AI, from strategy and platform development to project execution. The intended benefit of this approach is to enforce consistency, maintain tight control over governance, and achieve economies of scale [19]. However, this structure is ill-suited for the dynamic and diverse needs of a modern pharmaceutical organization. In practice, centralization tends to "clog the arteries" of innovation [20]. Business units are forced to wait in a queue for resources and approvals, creating a significant bottleneck that stifles agility and responsiveness. This delay encourages teams to develop workarounds or circumvent official processes altogether, leading to the proliferation of "shadow IT" and the use of unsanctioned, high-risk tools. Furthermore, a central team often lacks the deep, contextual domain expertise required to solve specific business problems effectively. This can result in the development of solutions that are technically elegant but practically irrelevant to the end-users in R&D, manufacturing, or commercial operations [19], [20]. The centralized model, therefore, mitigates certain risks related to standardization but introduces new, significant risks associated with slow innovation and the emergence of ungoverned technology use. B. The Decentralized Model: The Wild West of Silos In direct contrast to the centralized approach, a purely decentralized model empowers individual business units or functions to independently hire their own data scientists, select their own tools, and build their own AI solutions. The primary advantage of this model is its agility and its close alignment with specific business needs, as development is driven directly by those who understand the problems best [19], [21]. The failure mode of this approach, however, is equally severe. Uncoordinated decentralization leads to a fragmented and chaotic technological landscape. It results in duplicated efforts, as multiple teams across the organization may be solving the same problem independently, leading to wasted resources and capital. It creates inconsistent data interpretations and a proliferation of disparate tools, which erodes trust in shared data and makes enterprise-wide insights impossible to generate [6], [7], [19]. This model is the primary cause of the "islands of experimentation" phenomenon, where successful local solutions cannot be scaled or replicated elsewhere in the organization due to a lack of common standards, platforms, and governance [6]. From a risk perspective, this model is particularly dangerous in a regulated industry like pharmaceuticals. Without central oversight, it becomes exceedingly difficult to ensure consistent adherence to GxP, data privacy (e.g., GDPR, HIPAA), and ethical standards, exposing the entire enterprise to significant compliance and security risks. C. The Oscillation Trap and the Need for a Federated Approach Many organizations find themselves caught in an "oscillation trap," cyclically shifting between centralized and decentralized structures. After experiencing the bottlenecks of a centralized model, they decentralize to foster agility. When decentralization leads to chaos and inconsistency, they recentralize to regain control. This reactive cycle fails to address the fundamental issue: neither model is sufficient on its own [7]. This highlights the need for a third way—a purpose-built, hybrid structure that is intentionally designed to manage the inherent tension between the need for enterprise-wide standardization and the demand for business-unit-specific autonomy. This is the definition of a federated model [7], [22]. A federated approach is not a simple compromise but a distinct and deliberate organizational design. It recognizes that no single team can meet the full spectrum of an organization’s analytics needs, and no business unit can succeed in complete isolation. By strategically centralizing foundational elements while decentralizing innovation, a federated model provides a stable yet flexible structure to support scalable and responsible AI adoption. IV. THE HUB-AND-SPOKE MODEL:AFEDERATED FRAMEWORK FOR PHARMACEUTICAL AI The hub-and-spoke model is the practical implementation of a federated strategy for AI. It provides a clear and effective framework that balances the strengths of both centralized and decentralized approaches, creating a synergistic system for scalable innovation. The model is conceptually analogous to modern logistics networks, where a central hub coordinates core services and ensures efficiency, while distributed spokes provide localized access and tailored delivery [23], [24], [25]. In the context of AI, this translates to centralizing foundational capabilities while decentralizing domain-specific application development [21]. A. The Centralized Hub: The AI Center of Excellence (CoE) The hub of the model is an AI Center of Excellence (CoE), a dedicated, cross-functional organizational unit that serves as the central nervous system for all AI initiatives across the enterprise [26]. The CoE is not merely a technical support team; it is a strategic entity responsible for establishing the TABLE I AI IMPACT ACROSS THE PHARMACEUTICAL VALUE CHAIN Value Chain Stage Key AI Use Case Description of AI Application Quantifiable Impact / Key Metric Source(s) R&D Target Identification ML models analyze multi-omics data and scientific literature to predict novel drug targets. Increases probability of clinical success from traditional 10%. [1] Molecule Design AI predicts compound interactions and toxicity, screening millions of molecules rapidly. Reduces discovery-topreclinical timeline by up to 50%. [3] Clinical Development AI-enabled Site Selection AI identifies optimal trial sites and predicts enrollment performance. Boosts patient enrollment by 10-20% and shortens timelines by 6 months. [12] Trial Automation GenAI auto-drafts trial documents and AI copilots assist in trial management. Cuts process costs for documentation by up to 50%. [12] Manufacturing Predictive Maintenance AI analyzes sensor data from equipment to predict failures before they occur. Projected to generate $10 billion in value by 2030 from reduced downtime. [5] AI-powered Quality Control Computer vision systems identify product defects in real-time on production lines. Boosts QC productivity by 50-100%; reduces deviations by 65%. [3] Commercial Hyper-personalized Engagement Agentic AI dynamically adjusts call plans and sales pitches for HCPs in real-time. Moves beyond static "next best action" models for greater effectiveness. [18] Marketing Optimization AI analyzes patient and HCP data to optimize omnichannel marketing campaigns. Projected to capture 2535% of total AI value potential. [17] governance, platforms, standards, and talent base necessary for the entire organization to succeed with AI. Its primary functions are: 1) AI Strategy & Governance: The CoE defines the overarching enterprise AI vision and develops a strategic roadmap that aligns with key business objectives. It is responsible for establishing and enforcing robust governance frameworks, including policies for ethical AI, data privacy, and regulatory compliance (e.g., GxP, FDA guidelines). This central body ensures that all AI activities, regardless of where they occur in the organization, adhere to a consistent set of high standards [7], [22], [26]. 2) Platform & Technology Management: The CoE provides and manages a shared, enterprise-grade technology stack. This includes centralized data platforms, cloud computing resources, and a curated set of standardized AI and machine learning (ML) tools. By providing a common infrastructure, the hub dramatically reduces integration complexity—a hub-and-spoke architecture with 50 systems requires only 50 connections, a 96% reduction compared to the 1,225 point-to-point links in a decentralized model—and ensures that all teams are building on a secure and scalable foundation [27]. 3) Data Governance & Management: A core responsibility of the hub is to establish and enforce enterprisewide data governance. This includes defining standards for data quality, implementing master data management (MDM) practices, and overseeing data security and access control protocols. The CoE acts as the ultimate steward of the organization’s data assets, ensuring they are a reliable and trusted foundation for AI development [27], [28]. 4) Talent Development & Community Building: The CoE serves as a magnet for attracting and retaining top-tier AI talent. It also leads the charge in improving AI literacy across the entire organization by developing and delivering targeted upskilling and training programs. Crucially, the CoE fosters a community of practice, connecting data scientists and AI practitioners embedded in the various spokes to share knowledge, best practices, and reusable solutions [7], [29]. 5) Innovation & Advanced R&D: The hub is responsible for exploring cutting-edge AI research and undertaking complex, long-term, or high-risk AI projects that are beyond the scope or capability of any single business unit. This ensures the organization remains at the forefront of technological advancement. B. The Decentralized Spokes: Business-Embedded Innovation Teams The spokes of the model are agile, cross-functional teams that are embedded directly within the business units they serve, such as R&D, Manufacturing, Clinical Development, or Commercial [7]. Their defining characteristic is their proximity to the business, which allows them to deeply understand domain-specific challenges and opportunities. The spokes are the engines of localized, rapid, and relevant innovation. Their primary functions are: 1) Use Case Identification & Prioritization: Working closely with domain experts, the spoke teams identify and prioritize high-impact AI opportunities that address pressing business problems. They are responsible for building the business case for new AI initiatives and ensuring they align with the strategic priorities of their function [21], [30]. 2) Rapid Prototyping & Development: The spokes operate as agile squads, responsible for building, testing, and deploying AI solutions tailored to their specific needs. They leverage the standardized platforms, tools, and best practices provided by the central hub to accelerate development and ensure their solutions are scalable and compliant [21]. 3) Domain Expertise Integration: The success of any AI application in pharma hinges on the integration of deep domain knowledge. Spoke teams are inherently cross-functional, bringing together data scientists with pharmacologists, clinical scientists, process engineers, and compliance officers. This ensures that AI models are trained on the right data, that their outputs are contextually meaningful, and that the final solutions are trusted and adopted by end-users. 4) Adoption & Value Realization: The spoke teams are not only responsible for building AI tools but also for driving their adoption within the business unit. They are accountable for measuring and reporting on the value generated by their solutions, using metrics such as efficiency gains, cost savings, or revenue growth to demonstrate a clear return on investment [30]. The clear delineation of roles and responsibilities between the hub and the spokes is fundamental to the model’s success. Table II provides a detailed breakdown of this division of labor, illustrating the model’s balanced approach to AI scaling. V. GOVERNANCE AND LEADERSHIP IN THE HUB-AND-SPOKE STRUCTURE For the hub-and-spoke model to function effectively, it must be supported by a clear leadership structure and a collaborative, cross-functional team design. The right people in the right roles are essential to bridge the gap between central strategy and decentralized execution, ensuring that the entire system operates cohesively. A. Key Leadership Roles and Responsibilities Specific leadership roles are critical for providing accountability and direction within the federated structure. •Chief AI Officer (CAIO): This is a senior executive role, often reporting directly to the CEO or CTO, responsible for leading the AI CoE and driving the enterprise-wide AI strategy [31]. The CAIO is the ultimate owner of AI governance, ensuring that all initiatives align with business goals and comply with regulatory and ethical standards. A key part of this role is to act as an organizational catalyst, breaking down traditional silos and fostering the cross-departmental collaboration necessary for AI to be integrated effectively across the entire value chain [32]. The CAIO is accountable for demonstrating the ROI of AI investments and communicating the company’s AI vision to all stakeholders, from the board of directors to employees [32], [33]. •AI Product Owner: This role is the linchpin within each decentralized spoke. The AI Product Owner acts as the direct interface between the business stakeholders and the agile development team. They are responsible for translating complex business needs into a clear, prioritized product backlog of features and user stories [34], [35]. This individual owns the "what" and "why" of the AI product being developed within their domain, ensuring that it delivers tangible value to end-users. The role requires a unique hybrid skillset, combining deep business acumen and domain expertise with strong data literacy and a solid understanding of AI/ML concepts and capabilities [34], [36], [37]. •Data Governance Officer / Steward: These roles are typically housed within the central hub and are critical for operationalizing the data governance framework. The Data Governance Officer is responsible for setting data policies and standards, while Data Stewards, often assigned to specific data domains, are responsible for implementing those policies, ensuring data quality, defining metadata, and managing data access rights. They are the guardians of the organization’s data assets, making secure, high-quality data available to the spokes for AI development [28]. B. The Cross-Functional Agile Squad: The Engine of the Spokes The innovation and execution within the spokes are driven by small, agile, cross-functional squads. The composition of these teams is crucial; they cannot be composed solely of technical experts. True cross-functional collaboration is paramount for developing AI solutions that are not only technically sound but also relevant, compliant, and adopted by the business [38]. A typical agile squad within a pharmaceutical AI spoke should include: •Data Scientists & ML Engineers: The technical core of the team, responsible for data analysis, model development, training, and deployment. •Domain Experts: These are individuals with deep knowledge of the specific business area, such as pharmacologists in R&D, clinical scientists in development, or process engineers in manufacturing. They provide essential context, help define the problem, validate data and model outputs, and ensure the final solution is practically useful. •IT & Platform Engineers: Specialists who ensure that the AI solution can be seamlessly integrated with existing enterprise systems (e.g., ERP, LIMS, CRM) and that it runs efficiently on the company’s technology infrastructure. •Compliance & Quality Officers: Embedded members from the quality and compliance functions who ensure TABLE II DELINEATION OF RESPONSIBILITIES IN THE HUB-AND-SPOKE AI MODEL Functional Area Hub (AI CoE) Responsibilities Spoke (Business Unit) Responsibilities AI Strategy Sets enterprise-wide AI vision, strategic roadmap, and investment priorities. Ensures alignment with overall corporate strategy. Defines BU-specific AI priorities and use cases that align with the hub’s strategy. Builds business cases for local initiatives. Governance & Compliance Establishes and enforces global standards for GxP, data privacy (GDPR/HIPAA), and ethical AI. Manages regulatory interactions. Implements and adheres to hub-defined standards within the local context. Responsible for compliance of BUspecific applications. Technology & Infrastructure Provides, maintains, and secures centralized AI platforms, cloud infrastructure, and standardized MLOps toolsets. Utilizes and provides feedback on central platforms. Develops applications on the provided infrastructure. Manages local tool integration. Data Management Manages enterprise data governance, master data, data quality frameworks, and the central data lake/warehouse. Owns, curates, and governs domain-specific data products. Ensures local data adheres to enterprise quality standards. Talent & Culture Leads enterprise AI talent acquisition. Develops and deploys global AI literacy and upskilling programs. Fosters a community of practice. Drives adoption of AI tools within the business unit. Provides local, context-specific training. Acts as AI champions to build trust. Project Execution & Innovation Executes large-scale, cross-functional strategic AI projects. Conducts foundational AI research and explores emerging technologies. Identifies, prototypes, develops, and deploys BU-specific AI use cases. Focuses on rapid, agile delivery of value to the business function. that the AI development process adheres to GxP standards and other relevant regulations from the very beginning. This proactive involvement is far more effective than a reactive review at the end of the development cycle. •UX/CX Designers: Professionals focused on the end-user experience, ensuring that the AI tool is intuitive, easy to use, and effectively integrated into the daily workflows of its intended users. This is critical for driving adoption and realizing the tool’s value. By bringing these diverse skill sets together in a single, colocated team, the hub-and-spoke model accelerates decisionmaking, reduces handoffs between departments, and fosters a shared sense of ownership over the final product. VI. NAVIGATING IMPLEMENTATION CHALLENGES WITH A FEDERATED APPROACH The pharmaceutical industry faces a unique set of challenges when adopting AI, stemming from its stringent regulatory environment, the sensitivity of its data, and its complex operational workflows. The hub-and-spoke model is not just an efficient organizational structure; it is a purpose-built framework designed to systematically mitigate these critical challenges. A. Regulatory Compliance and Validation in GxP Environments The Challenge: AI systems, particularly complex "black box" models like deep neural networks, present significant validation challenges within the highly regulated Good Practice (GxP) environments that govern pharmaceutical development and manufacturing. Traditional software validation, based on deterministic inputs and outputs, is often inadequate for adaptive AI models [39], [40]. Regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are actively developing new guidance for AI, requiring organizations to demonstrate robust governance, transparency, and lifecycle management for their AI systems [41], [42]. Navigating this evolving landscape is a major hurdle for any pharmaceutical company. Hub-and-Spoke Mitigation: The federated model directly addresses this challenge by centralizing regulatory expertise and standardization within the hub (CoE). The CoE is responsible for interpreting new regulations (e.g., the EU AI Act, FDA AI guidance, EU GMP Annex 22) and translating them into actionable, enterprise-wide policies, procedures, and validation frameworks [39], [43]. The hub provides the spokes with pre-validated tools, standardized documentation templates (such as model cards for transparency), and expert guidance on demand. This approach ensures that all AI development across the organization, regardless of the specific use case, meets a consistent and high standard of regulatory scrutiny. It prevents the high-risk scenario where individual spoke teams attempt to interpret and implement complex regulations on their own, leading to inconsistent compliance and potential audit failures [44]. B. Data Governance, Security, and Quality The Challenge: The performance of any AI model is fundamentally dependent on the quality, integrity, and availability of the data used to train it. Pharmaceutical companies often struggle with data that is fragmented across legacy systems, stored in inconsistent formats, and of variable quality [5], [11]. Furthermore, the use of sensitive patient data and proprietary intellectual property introduces significant data security and privacy concerns, governed by regulations such as HIPAA and GDPR [3], [10], [45]. Hub-and-Spoke Mitigation: The hub-and-spoke model places the responsibility for enterprise data strategy and governance squarely within the CoE. The hub is tasked with breaking down data silos and establishing a "single source of truth" through robust master data management and the creation of a centralized, secure data foundation [28]. It implements enterprise-wide data quality standards, automated monitoring, and strong security and access control protocols. This centralized data management function ensures that the decentralized spokes can build their AI models on a foundation of trusted, high-quality, and secure data. This dramatically improves the reliability and accuracy of the resulting models while systematically reducing the risks associated with data breaches and non-compliance [27]. (This concept is expanded technically in Section VIII). C. Ethical AI, Transparency, and the "Black Box" Problem The Challenge: The lack of transparency and explainability in some advanced AI models creates a significant "trust gap," which can hinder adoption by clinicians, scientists, and regulators who need to understand the basis of an AI-generated recommendation [11], [14]. This "black box" nature also poses a risk of perpetuating or even amplifying hidden biases present in the training data, which could lead to inequitable or unsafe outcomes for certain patient populations [46]. Hub-and-Spoke Mitigation: The governance function of the central hub is the ideal place to establish and champion the organization’s ethical AI principles, focusing on fairness, accountability, and transparency, as demonstrated by companies like Novartis [47]. The CoE can mandate the use of explainable AI (XAI) techniques for high-risk applications, conduct systematic bias audits on algorithms, and establish clear guidelines for human oversight of AI-driven decisions. By centralizing this ethical oversight, the organization ensures that these critical considerations are applied consistently across all business functions, building trust with both internal and external stakeholders and mitigating the reputational and safety risks associated with biased or opaque AI. (This is expanded in Section IX-C). D. Change Management, AI Literacy, and Cultural Resistance The Challenge: The successful adoption of AI is as much a cultural challenge as it is a technical one. Common barriers include employee resistance to change, fear of job displacement, communication gaps between technical and business teams, and a general shortage of skilled AI talent within the organization [5], [14], [48], [49]. Hub-and-Spoke Mitigation: The federated model provides a two-pronged approach to overcoming these cultural hurdles. First, the central hub (CoE) takes responsibility for developing and deploying enterprise-wide AI literacy and upskilling programs. Crucially, these programs should be designed around specific roles and functions rather than being generic, onesize-fits-all training on tools. This ensures that employees understand how AI will specifically augment their work [44]. Second, the embedded spoke teams act as powerful agents of change within their respective business units. By demonstrating the value of AI in a local, familiar context, they can build trust and enthusiasm among their colleagues. They act as "AI Champions," bridging the gap between the central strategy and frontline operations and ensuring that AI tools are designed to collaborate with and empower human experts, rather than replace them [44], [50]. This dual approach fosters a culture of continuous learning and human-AI collaboration, which is essential for sustainable transformation. VII. VISUALIZING THE MODEL:ASTRUCTURAL AND ARCHITECTURAL BLUEPRINT While the previous sections have defined the roles and responsibilities of the federated model, this section provides a tangible blueprint for its organizational and technical implementation. This includes visualizing the organizational structure (Fig. 1) and the underlying cloud technology stack that enables it (Fig. 2). A. The Organizational Framework As illustrated in Fig. 1, the model is not strictly hierarchical but networked. The AI CoE (Hub) serves as a central enabler, connected to each business unit (Spoke). Critically, the spokes are not isolated from each other; the CoE fosters a "community of practice" (represented by dotted lines in the conceptual diagram) that connects data scientists and AI practitioners across the organization. This allows an innovation in the Manufacturing spoke (e.g., a new computer vision technique) to be shared, adapted, and reused by the R&D spoke (e.g., for analyzing microscopy images), preventing the siloed duplication of effort that plagues decentralized models. B. Reference Architecture for the AI CoE (Hub) The hub is not just a team of people; it is a shared technology platform. This platform must provide the tools for the entire AI lifecycle, from data ingestion to model deployment, while embedding the governance and compliance controls required by the pharmaceutical industry. Fig. 2 presents a cloud-agnostic reference architecture for this central platform. This architecture is layered: •Data Ingestion & Storage: The foundation allows spokes to ingest data from diverse sources (e.g., LIMS, ERP, clinical trial data, IoT sensors) into a central, secure, and GxP-compliant data lake. •Data Governance & Catalog: This layer, managed by the hub, provides a central data catalog, master data management, and data quality monitoring. This ensures all spokes are building on a "single source of truth." •AI/ML Platform: This is the core workbench. It provides both code-first (Notebooks, SDKs) and low-code (AutoML) tools, a feature store for sharing validated data features, and a central model registry. •MLOps & GxP Automation: This layer automates the CI/CD pipeline for models, but with GxP-specific guardrails, including automated validation checks, audit logging, and links to quality management systems (QMS). •Serving & Monitoring: The platform provides scalable, validated endpoints for deploying models and tools for AI CoE Hub Governance, Platforms, Talent, Strategy R&D Spoke (Agile Squad) Clinical Spoke (Agile Squad) Manufacturing Spoke (Agile Squad) Commercial Spoke (Agile Squad) Enablement Enablement Enablement Enablement Feedback, Needs Feedback, Needs Feedback, Needs Feedback, Needs Fig. 1. The Federated Hub-and-Spoke Organizational Model. The central AI CoE (Hub) provides foundational governance, platforms, and talent development (solid arrows), enabling decentralized, business-embedded Agile Squads (Spokes) to rapidly develop and deploy domain-specific AI solutions. Spokes provide feedback to the Hub (dashed arrows), and collaborate via a community of practice (dotted lines). monitoring their performance, data drift, and bias in realtime. C. Implementing the Hub on AWS and GCP This conceptual architecture can be realized using the managed services of major cloud providers, which accelerates development and simplifies GxP qualification [51]. 1) AWS Implementation: An AWS-based hub would leverage its mature ecosystem of AI and data services [52]. •Data Lake & Governance: Data is ingested via AWS Glue or Kinesis into Amazon S3 buckets. AWS Lake Formation is then used by the hub to build the central data catalog, enforce fine-grained access controls (e.g., column-level security for patient data), and provide an audit trail for data access [53]. •AI/ML Platform: Amazon SageMaker provides the end-to-end platform. Spokes would use SageMaker Studio for notebook-based development, SageMaker Feature Store to share curated features (e.g., "patient demographics"), and SageMaker Model Registry to version and store trained models with their GxP-required metadata [54]. •MLOps & GxP: SageMaker Pipelines is used to define and automate the MLOps workflows. The hub provides GxP-compliant pipeline templates that include steps for data validation, model testing, and generating evidence for the QMS. AWS Audit Trail and CloudTrail provide the immutable logs required for 21 CFR Part 11 compliance. 2) GCP Implementation: A Google Cloud (GCP) implementation offers a similar, highly integrated stack [55]. •Data Lake & Governance: Data is stored in Google Cloud Storage (GCS) and managed via BigQuery. The hub uses Dataplex as the intelligent data fabric to catalog, govern, and monitor data quality across distributed data domains, which aligns perfectly with the federated model [56]. Identity and Access Management (IAM) and Cloud Audit Logs secure the data. •AI/ML Platform: Vertex AI is the unified platform. Spokes use Vertex AI Workbench (managed notebooks), the Vertex AI Feature Store, and the Vertex AI Model Registry [57]. The hub can use the Model Registry to enforce approval workflows, ensuring a Quality Officer reviews a model’s validation package before it can be deployed. •MLOps & GxP: Vertex AI Pipelines automates the ML workflow. The hub can provide templates that integrate with Google Cloud Deployment Manager or Terraform to manage infrastructure-as-code (IaC), ensuring environments are provisioned consistently and in a validated state [58]. By centralizing the platform’s *management* in the hub, the organization achieves economies of scale and consistent governance. By providing *access* to this platform to the spokes, it empowers decentralized, rapid innovation. VIII. FEDERATED DATA ARCHITECTURE: FROM DATA SILOS TO DATA PRODUCTS A federated AI model cannot function without a federated data architecture. The hub-and-spoke model’s philosophy must extend to data ownership, moving from a centralized, monolithic data lake to a distributed "data mesh" [59]. A. The Challenge of Pharmaceutical Data As noted in Section VI-B, pharmaceutical data is notoriously siloed. R&D data resides in LIMS and electronic lab L5: Serving & Monitoring L4: MLOps & GxP Automation L3: AI/ML Platform L2: Data Governance & Catalog L1: Ingestion & Storage L0: Data Sources Model Serving Endpoints Monitoring Tools MLOps Pipelines with GxP Controls (e.g., SageMaker/Vertex Pipelines) Notebooks / SDKs (e.g., Studio) AutoML (e.g., Vertex AI) Feature Store Model Registry Data Governance (e.g., Lake Formation) Data Catalog (e.g., Dataplex) Ingestion Tools (e.g., Glue/Dataflow) Data Lake (S3/GCS) LIMS ERP IoT Sensors Clinical Data Lab Data Business Apps / BI Tools Feedback Fig. 2. Cloud Reference Architecture for the AI CoE (Hub). This layered platform provides a centralized, GxP-compliant foundation for the entire AI lifecycle. The Hub manages the platform (e.g., Data Governance, MLOps templates), while Spokes build and deploy models using its services. notebooks (ELNs), clinical data is in EDC (Electronic Data Capture) systems, and manufacturing data is in SCADA and MES (Manufacturing Execution Systems) [60]. A traditional centralized model attempts to copy all this data into a single data lake, creating a new bottleneck managed by a central team that lacks the domain context to understand, clean, or properly structure the data. B. Adopting a Data Mesh Philosophy A data mesh architecture inverts this model. It is built on four principles that align perfectly with the hub-and-spoke framework [59], [61]: 1) Domain-Oriented Ownership: The "spokes" (business units) own their data. The R&D spoke owns "R&D data," and the Manufacturing spoke owns "Manufacturing data." 2) Data as a Product: The spokes are responsible for transforming their raw, operational data into high-quality, curated "data products" that they serve to the rest of the organization. 3) Self-Serve Data Platform: The "hub" (CoE) is responsible for building and maintaining the underlying data infrastructure and platform (as described in Section VIIC) that *enables* the spokes to easily build, deploy, and share their data products. 4) Federated Computational Governance: The hub sets the global rules for data governance, quality, security, and interoperability. However, these rules are automated